Kinaset Therapeutics

Kinaset Therapeutics is a private, preclinical-stage biotech developing KN-002, a novel inhaled therapeutic for severe asthma. The company's strategy leverages direct pulmonary delivery to target inflammation locally, aiming for a broad-spectrum anti-inflammatory effect that could treat patients regardless of their asthma phenotype. Founded in 2020 and headquartered in Boston, Kinaset is advancing towards clinical trials with a focus on creating a convenient, non-invasive treatment option for a significant unmet medical need. The company operates in the competitive respiratory therapeutics space with a small molecule approach.

Inhaled delivery platform for small molecule drugs, focusing on direct pulmonary targeting to maximize local effect and minimize systemic exposure.

The severe asthma market is competitive, dominated by injectable biologic therapies targeting specific inflammatory pathways. Kinaset's KN-002 aims to differentiate itself as a convenient, inhaled, broad-spectrum anti-inflammatory agent, competing against both established biologics and new oral therapies in development.